Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

483.48 +2.41 (+0.50%)
Streaming Delayed Price Updated: 1:13 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Alnylam to Webcast Conference Call Discussing Third Quarter 2025 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Announces First Patient Dosed in ZENITH Global Phase 3 Cardiovascular Outcomes Trial of Zilebesiran
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Announces Pricing of Upsized Offering of $575 Million Convertible Senior Notes
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Announces Proposed Offering of $500 Million Convertible Senior Notes
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran’s Long-Term Cardiovascular Benefit in ATTR-CM
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam to Present Progress in Transforming the Treatment of Cardiovascular Disease with RNAi Therapeutics at European Society of Cardiology Congress 2025
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam to Webcast Presentation at Canaccord Genuity 45th Annual Growth Conference
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Period Progress
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam to Webcast Conference Call Discussing Second Quarter 2025 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Announces Promotion of Pushkal Garg to Chief Research and Development Officer
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program
From Instil Bio
Via GlobeNewswire
Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam to Webcast Presentation at Goldman Sachs 46th Annual Global Healthcare Conference
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Issues 2024 Corporate Responsibility Report
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
AMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the HELIOS-B Phase 3 Study Results at Heart Failure 2025 Congress
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Period Progress
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam to Webcast Conference Call Discussing First Quarter 2025 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam to Webcast Presentation at Needham 24th Annual Virtual Healthcare Conference
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology’s Annual Scientific Session 2025
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
FDA Approves Qfitlia™ (fitusiran), the First siRNA (RNAi Therapeutic) for the Treatment of Hemophilia A or B
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam to Webcast Presentation at Stifel 2025 Virtual CNS Forum
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Announces Retirement of Longtime Board Member, Dr. Phillip A. Sharp, Company Co-Founder and Industry Luminary
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Highlights Significant Pipeline Progress and Platform Innovation at R&D Day
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.